Abstract
MS is a well-known disease and chronic inflammation in the central nervous system is one of the diseases whose etiology, despite its well-known autoimmune nature, is still debated, although according to recent studies, the role of viruses such as EBV approved. Based on the different phases that are defined for MS and the degree of progression of the disease, a specific protocol and treatment process is defined for the patient. New and safe treatments for autoimmune diseases have been a constant challenge, although side effects, albeit on a small scale and with few reports, are inevitable; In this study, we tried to classify based on how it is used on drugs used in the treatment of this disease, and at the same time the progress and achievement of new cases such as the use of monoclonal antibodies, despite all the progress made. We still do not fully meet the treatment needs of MS based on studies, in other words, in the classification system and review study, in the group of injectable drugs, we reviewed drugs such as Daclizumab, Alemtuzumab, Natalizumab, Copaxone and Mitoxanthron. Oral drugs Fingolimod, Teriflunomide, and Siponimod were also discussed. In addition to discussing MS medication, we reviewed other treatments such as the use of bone marrow stem cells that were previously discussed in preventing bone marrow suppression during severe therapies such as chemotherapy in the treatment of MS.
Keywords:
Multiple Sclerosis, MS Treatments
References:
1. Gholamzad, M., Ebtekar, M., Ardestani, M.S. et al.“ A comprehensive review on the treatment approaches of multiple
sclerosis: currently and in the future.” Inflamm. Res. 68, 25–38 (2019).
2. Javan M-R, Seyfizadeh N, Aslani S, Farhoodi M, Babaloo Z. “Molecular analysis of interleukin-25 exons 1 and 2 and its
serum levels in Iranian patients with multiple sclerosis.” Am J Clin Exp Immunol. 2014;3(2):91.
3. Javan MR, Shahraki S, Safa A, Zamani MR, Salmaninejad A, Aslani S. “An interleukin 12 B single nucleotide
polymorphism increases IL-12p40 production and is associated with increased
disease susceptibility in patients with relapsing-remitting multiple sclerosis.” Neurol Res. 2017;39(5):435–41.
4. Javan MR, Aslani S, Zamani MR, Rostamnejad J, Asadi M, Farhoodi M, et al. “Downregulation of immunosuppressive
molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis.” Iran J Allerg Asthma Immunol.
2016;15(4):296
5. Azimi M, Ghabaee M, Moghadasi AN, Noorbakhsh F, Izad M. “Immunomodulatory function of Treg-derived exosomes
is impaired in patients with relapsing-remitting multiple sclerosis.” Immunol Res. 2018. 1–8.
6. Faissner, Simon, et al. "Progressive multiple sclerosis: from pathophysiology to therapeutic strategies." Nature Reviews
Drug Discovery 18.12 (2019): 905-922.
7. Dendrou CA, Fugger L, Friese MA.“ Immunopathology of multiple sclerosis.” Nat Rev Immunol. 2015;15(9):545–58.
8. Zéphir, Helene. "Progress in understanding the pathophysiology of multiple sclerosis." Revue neurologique 174.6 (2018):
358-363.
9. Bar-Or, Amit, et al. "Epstein–Barr virus in multiple sclerosis: theory and emerging immunotherapies." Trends in molecular
medicine 26.3 (2020): 296-310.
10. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple
sclerosis The 2013 revisions. Neurology. 2014;83(3):278–86.
11. Tanasescu R, Ionete C, Chou I-J, Constantinescu C. “Advances in the treatment of relapsing-remitting multiple sclerosis.”
Biomed J. 2014;37(2):41.
12. Preziosa, Paolo, et al. "Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory
activity." Journal of neurology (2021): 1-13.
13. Thomas RH, Wakefield RA. “Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.” Am J Health
Syst Pharm. 2015;72(1).
14. Bascuñana, Pablo, et al. "Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis." Drugs in R&D 20.3
(2020): 197-207.
15. Tintore, Mar, Angela Vidal-Jordana, and Jaume Sastre-Garriga. "Treatment of multiple sclerosis—success from bench to
bedside." Nature Reviews Neurology 15.1 (2019): 53-58.
16. McGinley, Marisa P., Carolyn H. Goldschmidt, and Alexander D. Rae-Grant. "Diagnosis and treatment of multiple
sclerosis: a review." Jama 325.8 (2021): 765-779.
17. Ali R, Nicholas RSJ, Muraro PA. “Drugs in development for relapsing multiple sclerosis.” Drugs. 2013;73(7):625–50.
18. Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y. Glatiramer acetate: “long-term safety and efficacy in relapsingremitting multiple sclerosis.” Expert Rev Neurother. 2015;15(6):575–86.
19. Johnson KP, Brooks B, Cohen J, Ford C, Goldstein J, Lisak R, et al. “Copolymer 1 reduces relapse rate and improves
disability in relapsing-remitting multiple sclerosis results of a phase III multicenter, double-blind, placebo-controlled trial.”
Neurology. 1995;45(7):1268–76.
20. Wynn, Daniel R. "Enduring clinical value of copaxone®(Glatiramer Acetate) in multiple sclerosis after 20 years of
use." Multiple Sclerosis International 2019 (2019).
21. Lugaresi A, Di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M.” Risk–benefit considerations in the treatment of
relapsing-remitting multiple sclerosis.” Neuropsychiatr Dis Treat. 2013;9:893.
22. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, et al.“ Effectiveness and cost-effectiveness of interferon
beta and glatiramer acetate in the UK multiple sclerosis risk sharing scheme at 6 years: a clinical cohort study with natural
history comparator.” Lancet Neurol. 2015;14(5):497–505.
23. Dhib-Jalbut, Suhayl. "Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis." Neurology 58.8
suppl 4 (2002): S3-S9.
24. Ford C, Goodman A, Johnson K, Kachuck N, Lindsey J, Lisak R, et al. “Continuous long-term immunomodulatory therapy
in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer
acetate. “ Mult Scler J. 2010;16(3):342–50.
25. Sorensen, Per Soelberg. "New management algorithms in multiple sclerosis." Current opinion in neurology 27.3 (2014):
246-259.
26. Craddock J, Markovic-Plese S.” Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal
antibodies, currently approved and in testing.” Expert Rev Clin Pharmacol. 2015;8(3):283–96.
27. Boneschi, Filippo Martinelli, et al. "Mitoxantrone for multiple sclerosis." Cochrane Database of Systematic Reviews 5
(2013).
28. Coles, Alasdair J. "Alemtuzumab therapy for multiple sclerosis." Neurotherapeutics 10.1 (2013): 29-33.
29. Hoepner, Robert, et al. "Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis." Journal of
central nervous system disease 6 (2014): JCNSD-S14049.
30. Baldassari, Laura E., and John W. Rose. "Daclizumab: development, clinical trials, and practical aspects of use in multiple
sclerosis." Neurotherapeutics 14.4 (2017): 842-858.
31. Steinman, Lawrence. "Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab." Nature reviews Drug
discovery 4.6 (2005): 510-518.
32. Polman CH, O’connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al.” A randomized, placebo-controlled
trial of natalizumab for relapsing multiple sclerosis.” N Engl J Med. 2006;354(9):899–910.
33. Miller D, Soon D, Fernando K, MacManus D, Barker G, Yousry T, et al.“ MRI outcomes in a placebo-controlled trial of
natalizumab in relapsing MS.” Neurology. 2007;68(17):1390–401.
34. Rommer P, Zettl U, Kieseier B, Hartung HP, Menge T, Frohman E, et al.“ Requirement for safety monitoring for approved
multiple sclerosis therapies: an overview.” Clin Exp Immunol. 2014;175(3):397–407.
35. McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al.” Stratification and monitoring of
natalizumab associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.” J
Neurol Neurosurg Psychiatry. 2015: jnnp-2015-311100.
36. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. “Risk of natalizumab-associated
progressive multifocal leukoencephalopathy.” N Engl J Med. 2012;366(20):1870–80.
37. Ho, Pei-Ran, et al. "Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple
sclerosis: a retrospective analysis of data from four clinical studies." The Lancet Neurology 16.11 (2017): 925-933.
38. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al.” Anti-JC virus antibody levels in serum or
plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.” Ann Neurol.
2014;76(6):802–1
39. Yamout, Bassem I., et al. "Efficacy and safety of natalizumab extended interval dosing." Multiple sclerosis and related
disorders 24 (2018): 113-116.
40. Clerico, Marinella, et al. "Extending the interval of natalizumab dosing: is efficacy preserved?." Neurotherapeutics 17.1
(2020): 200-207.
41. Cohen, Bruce A., et al. "The implications of immunogenicity for protein-based multiple sclerosis therapies." Journal of the
neurological sciences 275.1-2 (2008): 7-17.
42. Torkildsen Ø, Myhr KM, Bø L. “Disease-modifying treatments for multiple sclerosis—a review of approved medications.”
Eur J Neurol. 2016;23(S1):18–27.
43. Jones JL, Coles AJ. “Mode of action and clinical studies with alemtuzumab.” Exp Neurol. 2014;262:37–43.
44. Singer BA, editor. Parenteral treatment of multiple sclerosis: “the advent of monoclonal antibodies.” Seminars in
neurology; 2016. Thieme Medical Publishers
45. Coles, Alasdair J. "Alemtuzumab treatment of multiple sclerosis." Seminars in neurology. Vol. 33. No. 01. Thieme Medical
Publishers, 2013.
46. Hill-Cawthorne, Grant A., et al. "Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis."
Journal of Neurology, Neurosurgery & Psychiatry 83.3 (2012): 298-304.
47. Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, et al. “Safety and efficacy of the selective sphingosine
1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled,
phase 2 trial.” Lancet Neurol. 2016;15(4):373–81.
48. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al.” Alemtuzumab for patients with relapsing
multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.” Lancet. 2012;380(9856):1829–39.
49. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. “Alemtuzumab versus interferon beta 1a as
first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.” Lancet.
2012;380(9856):1819–28.
50. Meltzer, Ethan, et al. "Mitigating alemtuzumab-associated autoimmunity in MS: a “whack-a-mole” B-cell depletion
strategy." Neurology-Neuroimmunology Neuroinflammation 7.6 (2020).
51. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. “Regulatory CD56bright natural
killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis.” Proc Natl
Acad Sci. 2006;103(15):5941–6.
52. Wiendl, Heinz, and Catharina C. Gross. "Modulation of IL-2Rα with daclizumab for treatment of multiple
sclerosis." Nature Reviews Neurology 9.7 (2013): 394-404.
53. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis
(CHOICE study):” a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta.” Lancet
Neurol. 2010;9(4):381–90.
54. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, et al.” Daclizumab high-yield process in
relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.” The Lancet.
2013;381(9884):2167–75.
55. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, et al. Daclizumab high-yield process in
relapsing-remitting multiple sclerosis (SELECTION): “a multicentre, randomised, double-blind extension trial.” Lancet
Neurol. 2014;13(5):472–81
56. Milo, Ron. "The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis." Therapeutic
advances in neurological disorders 7.1 (2014): 7-21.
57. Cortese I, Ohayon J, Fenton K, Lee C-C, Raffeld M, Cowen EW, et al. “Cutaneous adverse events in multiple sclerosis
patients treated with daclizumab.” Neurology. 2016;86(9):847–55.
58. Shirley, Matt. "Daclizumab: a review in relapsing multiple sclerosis." Drugs 77.4 (2017): 447-458.
59. Baldassari LE, Rose JW. Daclizumab: “development, clinical trials, and practical aspects of use in multiple sclerosis.”
Neurotherapeutics. 2017:1-17.
60. Li J-M, Yang Y, Zhu P, Zheng F, Gong F-L, Mei Y-W.” Mitoxantrone exerts both cytotoxic and immunoregulatory effects
on activated microglial cells.” Immunopharmacol Immunotoxicol. 2012;34(1):36–41
61. Gonsette, R. E. "Mitoxantrone immunotherapy in multiple sclerosis." Multiple Sclerosis Journal 1.6 (1996): 329-332.
62. Millefiorini E, Gasperini C, Pozzilli C, D’andrea F, Bastianello S, Trojano M, et al.” Randomized placebo-controlled trial
of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.” J Neurol.
1997;244(3):153–9
63. Hartung H-P, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al.” Mitoxantrone in progressive multiple
sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.” Lancet. 2002;360(9350):2018–25.
64. Jain, Kewal K. "Evaluation of mitoxantrone for the treatment of multiple sclerosis." Expert Opinion on Investigational
Drugs 9.5 (2000): 1139-1149.
65. Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H.” Acute myeloid leukaemia induced by mitoxantrone
in a multiple sclerosis patient.” J Neurol. 2004 ;251(6):762–3.
66. Bar-Or, Amit. "Teriflunomide (Aubagio®) for the treatment of multiple sclerosis." Experimental neurology 262 (2014):
57-65.
67. Tanasescu R, Evangelou N, Constantinescu CS. “Role of oral teriflunomide in the management of multiple sclerosis.”
Neuropsychiatr Dis Treat. 2013;9:539
68. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. “Teriflunomide versus subcutaneous
interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.” Mult Scler J.
2014;20(6):705–16.
69. Gold, R., and J. S. Wolinsky. "Pathophysiology of multiple sclerosis and the place of teriflunomide." Acta neurologica
scandinavica 124.2 (2011): 75-84.
70. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. “Oral teriflunomide for patients with a first
clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.”
Lancet Neurol. 2014;13(10):977–86.
71. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, et al.” Pooled safety and tolerability data from
four placebo-controlled teriflunomide studies and extensions.” Mult Scler Relat Disord. 2016;5:97–104.
72. He, Dian, et al. "Teriflunomide for multiple sclerosis." Cochrane database of systematic reviews 3 (2016).
73. Hauser, Stephen L., et al. "Ofatumumab versus teriflunomide in multiple sclerosis." New England Journal of Medicine
383.6 (2020): 546-557.
74. Linker RA, Gold R.” Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side
effects.” Curr Neurol Neurosci Rep. 2013;13(11):394.
75. Prosperini, Luca, and Simona Pontecorvo. "Dimethyl fumarate in the management of multiple sclerosis: appropriate patient
selection and special considerations." Therapeutics and clinical risk management 12 (2016): 339.
76. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. “Placebo-controlled phase 3 study of oral BG12 for relapsing multiple sclerosis.” N Engl J Med. 2012;367(12):1098–107.
77. Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT et al. “Oral BG-12 (dimethyl
fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM: Evaluation of: Gold R, Kappos
L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;
367: 1098–107; and Fox RJ, Miller DH, Phillips JT, et al. “Placebo-controlled phase 3 study of oral BG-12 or glatiramer
in multiple sclerosis.” N Engl J Med 2012; 367: 1087–97. Expert Opin Pharmacother. 2013;14(15):2145–56.
78. Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, et al. “Long-term effects of delayed-release
dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.” Mult Scler J.
2017;23(2):253–65.
79. Sheremata, William, Andrew D. Brown, and Kottil W. Rammohan. "Dimethyl fumarate for treating relapsing multiple
sclerosis." Expert opinion on drug safety 14.1 (2015): 161-170.
80. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. “The immune modulator FTY720 targets
sphingosine 1-phosphate receptors.” J Biol Chem. 2002;277(24):21453–7.
81. Tanasescu R, Constantinescu CS. “Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.”
Expert Opin Drug Metab Toxicol. 2014;10(4):621–30
82. Groves A, Kihara Y, Chun J. Fingolimod: “direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and
implications in multiple sclerosis therapy.” J Neurol Sci. 2013;328(1):9–18.
83. Chun, Jerold, and Hans-Peter Hartung. "Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis." Clinical
neuropharmacology 33.2 (2010): 91.
84. Kappos L, Radue E-W, O’connor P, Polman C, Hohlfeld R, Calabresi P, et al.” A placebo-controlled trial of oral fingolimod
in relapsing multiple sclerosis.” N Engl J Med. 2010;362(5):387–401.
85. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. “Oral fingolimod or intramuscular interferon
for relapsing multiple sclerosis.” N Engl J Med. 2010;362(5):402–15.
86. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, et al.” Oral fingolimod in primary progressive
multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet.
2016;387(10023):1075–84.
87. yzenberg I, Hoepner R, Kleiter I. “Fingolimod for multiple sclerosis and emerging indications: appropriate patient
selection, safety precautions, and special considerations.” Ther Clin Risk Manag. 2016;12:261.
88. Pelletier, Daniel, and David A. Hafler. "Fingolimod for multiple sclerosis." New England Journal of Medicine 366.4
(2012): 339-347.
89. Meissner, Axel, and Volker Limmroth. "Update on the cardiovascular profile of fingolimod in the therapy of relapsingremitting multiple sclerosis (MS)." Multiple sclerosis and related disorders 8 (2016): 19-26.
90. Schur, Nadine, et al. "Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment
of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland."
PharmacoEconomics 39.5 (2021): 563-577.
91. Goodman, Andrew D., Nidhiben Anadani, and Lee Gerwitz. "Siponimod in the treatment of multiple sclerosis." Expert
opinion on investigational drugs 28.12 (2019): 1051-1057.
92. Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, van Marle SP, Legangneux E, Borell H, James AD, Meissner
A.” Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro
identification of human cytochrome P450 enzymes involved in its oxidative metabolism.” Drug metabolism and
disposition. 2018 Jul 1;46(7):1001-13.
93. Kapoor, Raju, et al. "Serum neurofilament light as a biomarker in progressive multiple sclerosis." Neurology 95.10 (2020):
436-444.
94. Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B,
Arnould S. “Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: doseblinded, randomized extension of the phase 2 BOLD study.” JAMA neurology. 2016 Sep 1;73(9):1089-98.
95. Chaudhry, Burhan Z., Jeffrey A. Cohen, and Devon S. Conway. "Sphingosine 1-phosphate receptor modulators for the
treatment of multiple sclerosis." Neurotherapeutics 14.4 (2017): 859-873.
96. Faissner, Simon, and Ralf Gold. "Progressive multiple sclerosis: latest therapeutic developments and future directions."
Therapeutic advances in neurological disorders 12 (2019): 1756286419878323.
97. Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C.”
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3
study.” The Lancet. 2018 Mar 31;391(10127):1263-73
98. Scott, Lesley J. "Siponimod: a review in secondary progressive multiple sclerosis." CNS drugs 34.11 (2020): 1191-1200.
99. Cao, Liujiao, et al. "Siponimod for multiple sclerosis." Cochrane Database of Systematic Reviews 11 (2021).
100.Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G,
Tomic D. “Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis”. Multiple
Sclerosis Journal. 2021 Sep;27(10):1564-76.
101.Schoedel, Kerri A., et al. "Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in
the treatment of multiple sclerosis: a review of literature and public data." Psychopharmacology (2021): 1-13.
102.Atkins, Harold L., and Mark S. Freedman. "Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned."
Neurotherapeutics 10.1 (2013): 68-76.
103.Giedraitiene N, Kizlaitiene R, Peceliunas V, Griskevicius L, Kaubrys G. “Selective cognitive dysfunction and physical
disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis.”
Scientific reports. 2020 Dec 4;10(1):1-9.
104.Nourbakhsh B, Rutatangwa A, Waltz M, Rensel M, Moodley M, Graves J, Casper TC, Waldman A, Belman A, Greenberg
B, Goyal M. “Heterogeneity in association of remote herpesvirus infections and pediatric MS.” Annals of clinical and
translational neurology. 2018 Oct;5(10):1222
105.Czarnowska A, Kapica-Topczewska K, Zajkowska O, Świerzbińska R, Chorąży M, Tarasiuk J, Zajkowska J, Kochanowicz
J, Kułakowska A. “Herpesviridae seropositivity in patients with multiple sclerosis: first Polish study.” European neurology.
2018;80(5-6):229-35.
106.Bakhuraysah, Maha M., Christopher Siatskas, and Steven Petratos. "Hematopoietic stem cell transplantation for multiple
sclerosis: is it a clinical reality?." Stem Cell Research & Therapy 7.1 (2016): 1-12.
107.Sahraian MA, Mohyeddin Bonab M, Baghbanian SM, Owji M, Naser Moghadasi A. “Therapeutic use of intrathecal
mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection.” Immunological
Investigations. 2019 Feb 17;48(2):160-8.
108.Kuan, Thomas Low Tat, Farahnaz Amini, and Marjan Sadat Seghayat. "Feasibility and toxicity of hematopoietic stem cell
transplant in multiple sclerosis." Iranian journal of basic medical sciences 20.7 (2017): 729.
109.Stepien A, Dabrowska NL, Maciagowska M, Macoch RP, Zolocinska A, Mazur S, Siennicka K, Frankowska E, Kidzinski
R, Chalimoniuk M, Pojda Z. “Clinical application of autologous adipose stem cells in patients with multiple sclerosis:
preliminary results.” Mediators of Inflammation. 2016 Oct;2016.
110.Gholamzad, Mehrdad et al. “Prophylactic and Therapeutic Effects of MOG-Conjugated PLGA Nanoparticles in C57Bl/6
Mouse Model of Multiple Sclerosis.” Advanced pharmaceutical bulletin vol. 11,3 (2021): 505-513.
doi:10.34172/apb.2021.058
111.Gholamzad, Mehrdad et al. “Intravenous Injection of Myelin Oligodendrocyte Glycoprotein-coated PLGA Microparticles
Have Tolerogenic Effects in Experimental Autoimmune Encephalomyelitis.” Iranian journal of allergy, asthma, and
immunology vol. 16,3 (2017): 271-281
112.Chountoulesi, Maria, and Costas Demetzos. "Promising nanotechnology approaches in treatment of autoimmune diseases
of central nervous system." Brain Sciences 10.6 (2020): 338.
